BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed VIR catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:5debe2a6711c82c9ce26@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:VIR P3 readout (est.): A Study to Evaluate Tobevibart+Elebsiran in 
 Participants With Chronic HDV Infection Not Virologically Suppressed With 
 Bulevirtide
DESCRIPTION:A Study to Evaluate Tobevibart+Elebsiran in Participants With C
 hronic HDV Infection Not Virologically Suppressed With Bulevirtide\nNCT071
 28550 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Vir Biotechnology\, Inc.
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nDate precision: month (shown on the first day)\nTicker VIR (confiden
 ce 0.9)\nSource: https://clinicaltrials.gov/study/NCT07128550\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07128550
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
